Valuation: Nektar Therapeutics

Market Cap 2.53B 2.19B 2.05B 1.87B 3.52B 241B 3.58B 24.06B 9.43B 121B 9.5B 9.29B 403B P/E 2026 *
-8.31x
P/E 2027 * -6.9x
Enterprise Value 2.53B 2.19B 2.05B 1.87B 3.52B 241B 3.58B 24.06B 9.43B 121B 9.5B 9.29B 403B EV / Sales 2026 *
61x
EV / Sales 2027 * 68.4x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+2.98%
Current month+6.03%
1 month+9.68%
3 months-4.81%
6 months+12.93%
Current year+77.22%
1 week 72
Extreme 72
77
1 month 64.24
Extreme 64.24
77
Current year 33.4
Extreme 33.4
109
1 year 22.5
Extreme 22.5
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
290.55
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 31/12/2006
Director of Finance/CFO 60 14/05/2026
Chief Tech/Sci/R&D Officer 52 30/06/2015
Director TitleAgeSince
Director/Board Member 72 31/07/2000
Chairman 69 30/04/1992
Director/Board Member 73 31/01/2007
Date Insider Type Main position Quantity % Market Cap.
24/07/26 Free

Chief Technology Officer

16,500 0.0488%
24/07/26 Free

Chief Executive Officer

57,200 0.1693%
30/06/26 Sell

Chief Technology Officer

-5,681 0.0168%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+2.98%+233.47%+435.18% 2.53B
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-0.48%+35.69%+18.69%+497.37% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
-0.68%+0.86%-15.67%-13.82% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-2.34%-7.29%+38.79%+141.26% 13.12B
Average +0.30%+359.05%+77.44%+228.19% 27.02B
Weighted average by Cap. -0.30%+346.59%+58.08%+168.42%

Financials

2026 *2027 *
Net sales 41.44M 35.92M 33.62M 30.68M 57.73M 3.95B 58.7M 394M 154M 1.98B 156M 152M 6.6B 36.99M 32.05M 30.01M 27.38M 51.52M 3.53B 52.39M 352M 138M 1.77B 139M 136M 5.89B
Net income -249M -216M -202M -184M -347M -23.76B -353M -2.37B -929M -11.89B -936M -915M -39.68B -351M -304M -285M -260M -489M -33.46B -497M -3.34B -1.31B -16.75B -1.32B -1.29B -55.87B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
11/08/26 US$74.93 +0.09% 144,307
10/08/26 US$74.86 -2.12% 486,880
07/08/26 US$76.48 +4.13% 899,157
06/08/26 US$73.45 +0.49% 403,616
05/08/26 US$73.09 +0.45% 581,029
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
74.86USD
Average target price
153.22USD
Spread / Average Target
+104.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock